Mechanisms of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Destruction of Dopaminergic Neurons

[1]  A. Cuello,et al.  Epidermal growth factor affects both glia and cholinergic neurons in septal cell cultures , 1992, Neuroscience.

[2]  K. Takeshige,et al.  1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.

[3]  C. Hoppel,et al.  Inhibition of mitochondrial respiration by analogues of the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium: structural requirements for accumulation-dependent enhanced inhibitory potency on intact mitochondria. , 1990, Archives of biochemistry and biophysics.

[4]  S. Carmichael,et al.  Mechanisms of Toxicity and Cellular Resistance to 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and 1‐Methyl‐4‐Phenylpyridinium in Adrenomedullary Chromaffin Cell Cultures , 1990, Journal of neurochemistry.

[5]  J. Casida,et al.  Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone. , 1990, Biochemical and biophysical research communications.

[6]  C. Marsden,et al.  1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset. , 1990, European journal of pharmacology.

[7]  G. Painter,et al.  Carrier-independent entry of 1-methyl-4-phenylpyridinium (MPP+) into adrenal chromaffin cells as a consequence of charge delocalization. , 1990, Biochemical and biophysical research communications.

[8]  R. Ramsay,et al.  Mechanism-based inactivation of monoamine oxidases A and B by tetrahydropyridines and dihydropyridines. , 1990, The Biochemical journal.

[9]  K. Chiba,et al.  Effects of N-methylmercaptoimidazole on the disposition of MPTP and its metabolites in mice. , 1990, European journal of pharmacology.

[10]  J. Langston,et al.  Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes , 1990, Journal of neurochemistry.

[11]  H. M. Geller,et al.  Potentiation by the Tetraphenylboron Anion of the Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and Its Pyridinium Metabolite , 1990, Journal of neurochemistry.

[12]  T. Hattori,et al.  Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death , 1990, Brain Research.

[13]  S. Vincent.  Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain , 1989, Neuroscience.

[14]  B. Hammock,et al.  MPTP-induced Parkinson-like disease in sheep: clinical and pathologic findings. , 1989, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[15]  R. Ramsay,et al.  Oxidation of Analogs of l‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine by Monoamine Oxidases A and B and the Inhibition of Monoamine Oxidases by the Oxidation Products , 1989, Journal of neurochemistry.

[16]  A. Marini,et al.  The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  C. Hoppel,et al.  Tetraphenylborate potentiates the respiratory inhibition by the dopaminergic neurotoxin MPP+ in both electron transport particles and intact mitochondria. , 1989, Biochemical and biophysical research communications.

[18]  W. Nicklas,et al.  Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs. , 1989, The Journal of pharmacology and experimental therapeutics.

[19]  J. LaManna,et al.  Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.

[20]  P. Sonsalla,et al.  Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. , 1989, The Journal of pharmacology and experimental therapeutics.

[21]  R. Ramsay,et al.  Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria. , 1989, Biochemical and biophysical research communications.

[22]  T. Aiuchi,et al.  Enhancement by tetraphenylboron of inhibition of mitochondrial respiration induced by 1-methyl-4-phenylpyridinium ion (MPP+) , 1988, Neurochemistry International.

[23]  C. Ragan,et al.  Structural studies on mitochondrial NADH dehydrogenase using chemical cross-linking. , 1988, The Biochemical journal.

[24]  A. Zuddas,et al.  Covalent protein binding of a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mouse and monkey brain in vitro and in vivo. , 1988, Biochemical pharmacology.

[25]  K. Chiba,et al.  Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. , 1988, The Journal of pharmacology and experimental therapeutics.

[26]  K. Schaich,et al.  An electrochemical study of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its oxidation products☆ , 1988 .

[27]  P. Sonsalla,et al.  Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Kalyanaraman,et al.  Oxygen activation during the interaction between MPTP metabolites and synthetic neuromelanin--an ESR-spin trapping, optical, and oxidase electrode study. , 1988, Biochemical and biophysical research communications.

[29]  S. Markey,et al.  Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin. , 1988, Chemical research in toxicology.

[30]  S. Werner,et al.  Pethidine analogues, a novel class of potent inhibitors of mitochondrial NADH: ubiquinone reductase. , 1988, Biochemical pharmacology.

[31]  W. Weiner,et al.  Selective Destruction of Cultured Dopaminergic Neurons from Fetal Rat Mesencephalon by 1‐Methyl‐4‐Phenylpyridinium: Cytochemical and Morphological Evidence , 1988, Journal of neurochemistry.

[32]  J. Barker,et al.  1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Metabolism and l‐Methyl‐4‐Phenylpyridinium Uptake in Dissociated Cell Cultures from the Embryonic Mesencephalon , 1988, Journal of neurochemistry.

[33]  S. Harik,et al.  Chemical oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its in vivo metabolism in rat brain and liver. , 1988, Biochemical and biophysical research communications.

[34]  N. Castagnoli,et al.  Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+. , 1988, Chemical research in toxicology.

[35]  N. Castagnoli,et al.  The formation of reactive intermediates in the MAO-catalyzed oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1988, Toxicology.

[36]  R. Kalaria,et al.  On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. , 1988, The Journal of pharmacology and experimental therapeutics.

[37]  James M. Wright,et al.  α-Tocopherol and β-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1987, Journal of the Neurological Sciences.

[38]  D. Greenblatt,et al.  Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP. , 1987, Biochemical and biophysical research communications.

[39]  D. D. Di Monte,et al.  Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1987, Biochemical and biophysical research communications.

[40]  L. Sayre,et al.  Model study on the bioreduction of paraquat, MPP+, and analogs. Evidence against a "redox cycling" mechanism in MPTP neurotoxicity. , 1987, Biochemical and biophysical research communications.

[41]  J. Langston,et al.  The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. , 1987, European journal of pharmacology.

[42]  P. Sonsalla,et al.  Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. , 1987, The Journal of pharmacology and experimental therapeutics.

[43]  C. Markham,et al.  Immunohistochemical localization of monoamine oxidase-B in the cat brain: Clues to understanding N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity , 1987, Experimental Neurology.

[44]  B. Kalyanaraman,et al.  Evidence for the one-electron oxidation of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+). , 1987, Biochemical and biophysical research communications.

[45]  R. Ramsay,et al.  Inhibition of NADH oxidation by pyridine derivatives. , 1987, Biochemical and biophysical research communications.

[46]  S. Banni,et al.  MPTP fails to induce lipid peroxidation in vivo. , 1987, Biochemical pharmacology.

[47]  R. Ramsay,et al.  Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase B. , 1987, Biochemistry.

[48]  S. Harik,et al.  On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. , 1987, The Journal of pharmacology and experimental therapeutics.

[49]  R. Kalaria,et al.  Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Langston,et al.  Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+ , 1987, Neuroscience Letters.

[51]  Y. Mizuno,et al.  Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.

[52]  K. Jones,et al.  4-Phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets , 1987, Neuroscience Letters.

[53]  Y. Mizuno,et al.  Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.

[54]  J. Langston,et al.  4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity. , 1987, Life sciences.

[55]  W. Weiner,et al.  1-Methyl-4-phenylpyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons , 1986, Neuroscience Letters.

[56]  K. Tipton,et al.  Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, The Biochemical journal.

[57]  V. Yong,et al.  Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse , 1986, Neuroscience Letters.

[58]  M. Kindt,et al.  Prevention of the Nigrostriatal Toxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine by Inhibitors of 3,4‐Dihydroxyphenylethylamine Transport , 1986, Journal of neurochemistry.

[59]  E. Melamed,et al.  Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. , 1986, European journal of pharmacology.

[60]  E. Melamed,et al.  Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) , 1986, Neuroscience Letters.

[61]  R. Ramsay,et al.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.

[62]  M. Del Zompo,et al.  A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase. , 1986, The Journal of pharmacology and experimental therapeutics.

[63]  J. Vitorica,et al.  Involvement of mitochondria in the age-dependent decrease in calcium uptake of rat brain synaptosomes , 1986, Brain Research.

[64]  R. Ramsay,et al.  Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.

[65]  D. D. Di Monte,et al.  Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. , 1986, Biochemical and biophysical research communications.

[66]  D. D. Di Monte,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. , 1986, Biochemical and biophysical research communications.

[67]  S. Harik,et al.  Comparative toxicity of MPTP, MPP+ and 3,3-dimethyl-MPDP+ to dopaminergic neurons of the rat substantia nigra. , 1986, European journal of pharmacology.

[68]  N. Lenn,et al.  Migraine with tardy pleocytosis , 1986, Neurology.

[69]  W. Nicklas,et al.  Studies on the Neurotoxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine: Inhibition of NAD‐Linked Substrate Oxidation by Its Metabolite, 1‐Methyl‐4‐Phenylpyridinium , 1986, Journal of neurochemistry.

[70]  A. Brossi,et al.  Studies on the mechanism of MPTP oxidation by human liver monoamine oxidase B , 1986, FEBS letters.

[71]  B. Frei,et al.  N‐Methyl‐4‐phenylpyridine (MMP+ together with 6‐hydroxydopamine or dopamine stimulates Ca2+ release from mitochondria , 1986, FEBS letters.

[72]  G. Krishna,et al.  Formation of superoxide and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion (MPP+): reductive activation by NADPH cytochrome P-450 reductase. , 1986, Biochemical and biophysical research communications.

[73]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[74]  R. Ramsay,et al.  Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.

[75]  S. Markey,et al.  1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. , 1986, Life sciences.

[76]  J. Cashman,et al.  Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations. , 1986, Molecular pharmacology.

[77]  R. Ramsay,et al.  Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.

[78]  V. Yong,et al.  Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment , 1986, Neuroscience Letters.

[79]  I. Kopin,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. , 1985, European journal of pharmacology.

[80]  R. Carelli,et al.  Ascorbic acid reduces the dopamine depletion induced by MPTP , 1985, Neuropharmacology.

[81]  J. Poirier,et al.  1-Methyl-4-phenyl-pyridinium-induced inhibition of nicotinamide adenosine dinucleotide cytochrome c reductase , 1985, Neuroscience Letters.

[82]  A. J. Bradbury,et al.  The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety , 1985, Neuroscience Letters.

[83]  R. M. Rose,et al.  Distinct monoamine oxidase A and B populations in primate brain. , 1985, Science.

[84]  E. Melamed,et al.  Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. , 1985, European journal of pharmacology.

[85]  L. Peterson,et al.  Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, Journal of medicinal chemistry.

[86]  R. Clavier,et al.  Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse , 1985, Neuroscience Letters.

[87]  M. Zompo,et al.  1 ‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine: Correspondence of Its Binding Sites to Monoamine Oxidase in Rat Brain, and Inhibition of Dopamine Oxidative Deamination In Vivo and In Vitro , 1985, Journal of neurochemistry.

[88]  R. Duvoisin,et al.  Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats , 1985, Neuroscience Letters.

[89]  T. Baillie,et al.  Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. , 1985, Journal of medicinal chemistry.

[90]  R. Duvoisin,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice , 1985, Neuroscience Letters.

[91]  A. Carlsson,et al.  Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain , 1985, Neuropharmacology.

[92]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[93]  C. Mytilineou,et al.  1-methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture , 1985, Neuroscience Letters.

[94]  M. Jarvis,et al.  Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) , 1985, Neuropharmacology.

[95]  L. Pearce,et al.  Cellular localization of MAO A and B in brain: Evidence from kainic acid lesions in striatum , 1985, Brain Research.

[96]  A. Brossi,et al.  Further insight into the mode of action of the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, FEBS letters.

[97]  E. Sundström,et al.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. , 1985, European journal of pharmacology.

[98]  J. Poirier,et al.  The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. , 1985, Biochemical and biophysical research communications.

[99]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[100]  B. Parsons,et al.  Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]parygyline binding to monoamine oxidase , 1985, Brain Research.

[101]  J. Vitorica,et al.  Impairment of glutamate uptake and absence of alterations in the energy-transducing ability of old rat brain mitochondria , 1985, Mechanisms of Ageing and Development.

[102]  R. Fuller,et al.  Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1985, The Journal of pharmacology and experimental therapeutics.

[103]  S. Markey,et al.  Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. , 1985, Life sciences.

[104]  J. Langston,et al.  Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? , 1985, Life sciences.

[105]  N. Castagnoli,et al.  Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.

[106]  S. Snyder,et al.  Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. , 1984, European journal of pharmacology.

[107]  M. Yahr,et al.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.

[108]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[109]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[110]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[111]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[112]  C. Mytilineou,et al.  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. , 1984, Science.

[113]  B. Parsons,et al.  High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase. , 1984, European journal of pharmacology.

[114]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[115]  C. Marsden,et al.  Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. , 1984, Biochemical pharmacology.

[116]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[117]  S. Markey,et al.  Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. , 1984, European journal of pharmacology.

[118]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[119]  S. Markey,et al.  The Neurotoxicity of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the Monkey and Man , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[120]  L. Olson,et al.  Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. , 1984, European journal of pharmacology.

[121]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[122]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[123]  J. Crapo,et al.  Biology of disease: free radicals and tissue injury. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[124]  E. Mimnaugh,et al.  Activation of pharmacologic agents to radical intermediates. Implications for the role of free radicals in drug action and toxicity. , 1982, Biochemical pharmacology.

[125]  X. Breakefield,et al.  Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[126]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[127]  S. Cagen,et al.  A mechanism of paraquat toxicity in mice and rats. , 1976, Toxicology and applied pharmacology.

[128]  H. Rottenberg.  Membrane potential and surface potential in mitochondria: Uptake and binding of lipophilic cations , 2005, The Journal of Membrane Biology.

[129]  E. Scarnati,et al.  The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys , 2004, Experimental Brain Research.

[130]  M. Jarvis,et al.  1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced neurotoxicity in the rat: Characterization and age‐dependent effects , 1990, Synapse.

[131]  S. Gee,et al.  A sheep model for MPTP induced Parkinson-like symptoms. , 1989, Life sciences.

[132]  R. Ramsay,et al.  Bioactivation of MPTP: reactive metabolites and possible biochemical sequelae. , 1987, Life sciences.

[133]  D. D. Di Monte,et al.  Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes. , 1987, Chemico-biological interactions.

[134]  C. Ragan.  Structure of NADH-Ubiquinone Reductase (Complex I) , 1987 .

[135]  K. Jellinger,et al.  Cellular action of MAO inhibitors. , 1987, Journal of neural transmission. Supplementum.

[136]  M. Del Zompo,et al.  Primate-rodent 3H-MPTP binding differences, and biotransformation of MPTP to a reactive intermediate in vitro. , 1986, Journal of neural transmission. Supplementum.

[137]  D. Jacobowitz,et al.  Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. , 1984, Psychopharmacology bulletin.

[138]  B. Goldstein,et al.  Decrease in mouse lung and liver glutathione peroxidase activity and potentiation of the lethal effects of ozone and paraquat by the superoxide dismutase inhibitor diethyldithiocarbamate. , 1979, Biochemical pharmacology.

[139]  G. R. Williams,et al.  Inhibition of electron and energy transfer in mitochondria. I. Effects of Amytal, thiopental, rotenone, progesterone, and methylene glycol. , 1963, The Journal of biological chemistry.